People of a lower socioeconomic status (SES) generally have poorer health status and higher mortality than people of higher SES ([@bib16]; [@bib23]), also with respect to cancer, with in general higher incidence rate of all cancers combined among people from lower socioeconomic groups ([@bib7]). A differential distribution of known risk factors for specific neoplasms between SES groups seems a likely explanation for the above inequalities. For example, the prevalence of smokers has become higher among lower classes ([@bib19]; [@bib35]), probably resulting in higher rates of cancer of the lung, larynx, mouth, pharynx, oesophagus, and bladder ([@bib31]; [@bib34]; [@bib38]). However, smoking is not only related to cancer but also to chronic obstructive pulmonary diseases (COPD) and cardiovascular diseases ([@bib8]). Hence, the high prevalence of comorbidity among lung cancer patients ([@bib14]). Socioeconomic status may thus be associated with comorbidity among cancer patients. Thus, medical doctors are presented with a heterogeneous group of cancer patients, for whom appropriate individual treatment must be chosen, taking concomitant conditions into account ([@bib1]; [@bib20]; [@bib15]; [@bib21]; [@bib22]; [@bib41]).

We studied in a large population-based group of cancer patients the prevalence of comorbidity according to SES, not only by number of concomitant diseases, but also for specific diseases that affect patients with the various tumour sites.

Materials and methods
=====================

The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the south of the Netherlands (2.4 million inhabitants, 15% of the Dutch population); it also records serious comorbidity according to an adaptated list ([@bib6]). Chronic obstructive pulmonary diseases, cardio- and cerebrovascular diseases, peripheral arterial disease, other malignancies, and diabetes mellitus, connective tissue diseases, rheumatoid arthritis, kidney, bowel, and liver diseases, dementia, tuberculosis and other chronic infections were also recorded. For most analyses peripheral arterial disease was included in the cardiovascular diseases, although gastrointestinal diseases were grouped (gastric diseases, Crohn\'s disease, ulcerative colitis, liver cirrhosis, and hepatitis). Comorbidity was defined as life-shortening disease that was present at the time of cancer diagnosis and/or received treatment or surveillance. Trained registry personnel actively collect data on diagnosis, staging, and treatment from the medical records after notification by pathologists and medical registration offices. Previous admissions, letters from and to general practitioners and other specialists, the medical history and preoperative screening were used as sources.

Patients with cancer of the oesophagus, stomach, colon or rectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, bladder, kidney, and non-Hodgkin\'s lymphoma (NHL), newly diagnosed between 1997 and 2006 (*n*=72 153), were included in this study; cancers diagnosed at autopsy (*n*=369) were excluded.

Statistics Netherlands developed an indicator of SES, using individual fiscal data on the economic value of the home and household income, and is provided at aggregated level for each postal code (covering an average of 17 households). Socioeconomic status was categorised as low (deciles 1--3), medium (deciles 4--7), or high social class (deciles 8--10), and a separate class for postal codes for a long-term care providing institution (such as a nursing home; [@bib40]). We calculated the distribution of cancer patients across socioeconomic strata according to tumour localisation, also by gender and age. Patients for whom the SES was unknown (*n*=766, 1%) or for whom the postal code included a care providing institution (*n*=3569, 5%), as well as those with unknown comorbidity (*n*=8399, 12%) were excluded from the analyses of SES and comorbidity. Differences in distribution were tested with the *χ*^*2*^ test. Logistic regression analyses of the odds of having a specific concomitant disease were performed age- and gender-adjusted for all tumour sites combined, and according to tumour site for four concomitant diseases separately; cardiovascular disease, COPD, diabetes mellitus, and gastrointestinal disease. Statistical significance of an overall effect of SES on the prevalence of a specific condition was tested using the *χ*^2^-likelihood ratio test. Crude 1-year survival rates were calculated for all studied tumours combined and for the most important tumour sites separately. Cox\'s regression models were used to compute multivariate rates (hazard ratio=HR) and 95% confidence intervals (95% CI). The relative contribution (%) of adding comorbidity to the model was calculated as follows: ((HR model A−HR model B)/(HR model A−1)) × 100, where A is the basic model (age- and gender-adjusted) and in model B comorbidity is added to model A. All statistical analyses were performed using SAS V9.12 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Male cancer patients were older than female patients ([Table 1](#tbl1){ref-type="table"}), the median age being 69 and 64 years, respectively (*P*\<0.0001). At the time of the diagnosis of the cancer 71% of male and 58% of female cancer patients had at least one concomitant disease. The most frequent concomitant condition for males with cancer was cardiovascular disease (23%), for women hypertension (20%), among cancer patients older than 70 the prevalence of these diseases was 34% and 31%, respectively. In the subgroup of cancer patients with two or more concomitant diseases, the most frequent combination of diseases among males was cardiovascular disease with hypertension (14%) and in females diabetes with hypertension (21%).

The proportion of patients by SES varied for the different tumour sites ([Table 2](#tbl2){ref-type="table"}). Patients under age 70 with stomach, lung, bladder, or cervical cancer more often had low SES. High SES was more frequent among patients with melanoma or breast, colorectal, or prostate cancer in this age group.

Among patients aged 70+ with cancer of the oesophagus, stomach, or lung, low SES was clearly over-represented. High SES was more frequent among patients with prostate cancer or NHL.

For all tumour localisations the proportion of patients without comorbidity was highest in the high SES group ([Figure 1](#fig1){ref-type="fig"}). A gradient towards more concomitant conditions appeared in lower SES groups (*P*\<0.001), which had a significantly higher risk of cardiovascular disease (OR~low\ *vs*\ high\ SES~=1.4, 95% CI: 1.3--1.5), COPD (OR=1.8 (1.7--1.9)), diabetes mellitus (OR=1.5 (1.4--1.6)), cerebrovascular disease (OR=1.5 (1.4--1.7)), tuberculosis (OR=1.3 (1.1--1.6)), dementia (OR=1.3 (1.0--1.8)), gastrointestinal disease (OR=1.5 (1.4--1.6)), and two or more concomitant conditions (OR=1.8 (1.7--1.9)) in addition to their cancer ([Table 3](#tbl3){ref-type="table"}). The risk of having cancer and also at least one other serious concomitant disease was 50% higher in the low SES than in the high SES group (OR=1.5 (1.4--1.6)).

For four concomitant conditions we stratified by tumour localisation ([Figure 2](#fig2){ref-type="fig"}). The risk of cardiovascular disease among low compared with high SES patients was significantly higher (1.4--1.6 times) for patients with stomach, colorectal, lung, breast, prostate, and bladder cancer. The risk of COPD was elevated among low SES patients with cancer of the stomach, colorectum, pancreas, lung, breast, corpus uteri, prostate, and kidney (OR\'s ranging from 1.4 to 2.2). The risk of diabetes mellitus was highest among people from low SES with breast cancer (OR=2.0 (1.2--2.4)) and the risk of gastrointestinal diseases was highest among patients with oesophageal cancer (OR=2.0 (1.2--3.4)).

Crude 1-year survival of cancer patients from lower SES was worse compared with the highest SES for all tumour sites combined and for the major sites separately ([Table 4](#tbl4){ref-type="table"}). The age-adjusted risk of death was significantly elevated for both men (HR~low\ *vs*\ high\ SES~=1.40, 95% CI: 1.3--1.4) and women (HR 1.40 (1.3--1.5)). Adding comorbidity to the model reduced HR to 1.35 for men and 1.34 for women. The relative contribution of comorbidity in explaining the inequality in 1-year survival varied from 0% for lung cancer to 33% among female colorectal cancer patients.

Discussion
==========

To our knowledge, this is the first large population-based study to demonstrates the impact of SES on the prevalence of concomitant diseases among cancer patients, with increased prevalence of comorbidity in lower socioeconomic strata for each type of cancer. Cancer patients with low SES had a 50% higher risk of suffering from at least one other serious disease compared with those with high SES. The prevalence of comorbidity was significantly higher with newly diagnosed cancer of lower compared with higher SES for all 14 cancer sites studied. The diseases significantly related to SES among cancer patients were cardiovascular disease, COPD, diabetes mellitus, cerebrovascular disease, tuberculosis, diseases of the central nervous system, and gastrointestinal disease. Although both the prevalence of comorbidity and the proportional distribution of SES vary significantly among tumour types, the gradient of more comorbidity from high to low SES was apparent among all tumour types.

Smoking is probably responsible for the higher risk of cardiovascular disease, COPD, and cerebrovascular disease among low SES groups ([@bib8]; [@bib34]). This is confirmed by the higher prevalence of those diseases among patients with smoking-related tumours: cancers of the stomach, lung, bladder, and kidney ([@bib14]; [@bib18]). Diabetes was more frequent among low SES for patients with cancers of the colorectum, pancreas, lung, breast, corpus uteri or prostate, or melanoma or NHL. Diabetes has been linked to pancreas cancer ([@bib12]; [@bib17]) either as a risk factor or as the clinical manifestation of the cancer itself ([@bib46]). Diabetes has also been associated with an increased risk for breast ([@bib47]), endometrial ([@bib26]), and colorectal cancer ([@bib28]) probably because of a relation with obesity ([@bib30]). Substantial evidence exists for the association of obesity with low SES ([@bib33]; [@bib45]; [@bib24]).

The prevalence of gastrointestinal diseases was highest for low SES patients with oesophageal, colorectal, lung, breast, prostate or kidney cancer, or NHL. Oesophageal cancer has also been associated with gastrointestinal diseases ([@bib18]). A lower consumption of vegetables, fruit, and fibres, which may protect from oesophageal ([@bib39]; [@bib37]) and colorectal cancer ([@bib27]; [@bib25]; [@bib42]; [@bib36]; [@bib5]; [@bib9]), has been reported among lower SES ([@bib43]; [@bib11]; [@bib44]).

We used an indicator of SES based on the postal code of a residential area. This aggregate covers a very small geographical area, and thus represents a reliable approximation of individual SES. Furthermore, routinely collected income tax data (no questionnaires or interviews) have been found to provide reliable estimates of household income. Previous studies have proven that socioeconomic differences based on neighbourhood data tend to reflect such differences well at the individual level ([@bib3], [@bib4]; [@bib32]). Furthermore, this objective measure of SES is also applicable to older women (born before 1955), whose occupation or education does not always properly reflect their social class ([@bib2]).

Previously, we found that patients with comorbidity were often treated less aggressively, if alternative treatment strategies were available. Except for patients with a tumour with poor survival, comorbidity has an independent prognostic effect ([@bib13]). This negative impact of comorbidity on survival of cancer might have several mechanisms: the increased risk of death due to the comorbid condition itself, more contra-indications for the cancer treatment, more indications for dose reduction and a higher rate of treatment-related complications such as infections and cardiovascular events. In several of our recent studies, the adverse effects of comorbidity on survival appeared to be independent of treatment, so less aggressive treatment could not (fully) account for the observed differences in survival between patients with and without comorbidity ([@bib29]; [@bib21]; [@bib22]; [@bib41]; [@bib10]). As SES represents a combination of lifestyle, health, and risk of suboptimal treatment, cancer patients with comorbidity could also (partly) explain the poorer prognosis. Although an in-depth study remains necessary to reveal whether stage at diagnosis and treatment contributed to the SES gradient in survival, also for longer survival periods, our preliminary analyses demonstrated a clear gradient in 1-year survival rates, which could partly be attributed to comorbidity.

Our study shows considerable variation in comorbidity by tumour type and a higher risk of concomitant disease among patients from lower SES. Given the aetiology of the type of tumours as well as the aetiology of the concomitant diseases that occur more frequently among patients from low SES background, a lot can probably be gained from preventive measures related to lifestyle (such as smoking and obesity). Considering survival is worse for patients of low SES, our results stress the need for reduction of socioeconomic differences in health.
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![Number of concomitant diseases among cancer patients diagnosed in 1997--2006 in the Southeastern Netherlands. ^\*^Distribution of number of concomitant diseases significantly different from the highest socioeconomic status category.](6605949f1){#fig1}

![Risk of four concomitant diseases among cancer patients with the lowest socioeconomic status (SES) compared with those with the highest SES (=reference, 1.00) according to tumour localisation with adjustment for age and gender. ^\*^95% confidence interval does not include 1.00; \# No reliable estimate because \<5 cases in reference category.](6605949f2){#fig2}

###### Description of all cancer patients diagnosed with selected tumours between 1997 and 2006 in the Eindhoven Cancer Registry

                                                        **Males**   **Females**   **Total**                 
  ----------------------------------------------------- ----------- ------------- ----------- ---- -------- -----
  *Tumour localisation*                                                                                     
   Oesophagus                                           1079        3             398         1    1477     2
   Stomach                                              1723        5             1032        3    2755     4
   Colorectal                                           6815        19            6014        17   12 829   18
   Pancreas                                             907         2             849         2    1756     2
   Lung                                                 9354        26            3591        10   12 945   18
   Melanoma                                             1405        4             1899        5    3304     5
   Breast                                               ---                       14 859      41   14 859   20
   Cervix uteri                                         ---                       725         2    725      1
   Corpus uteri                                         ---                       2128        6    2128     3
   Ovary                                                ---                       1540        4    1540     2
   Prostate                                             9987        27            ---              9987     14
   Kidney                                               1201        3             806         2    2007     3
   Urinary bladder                                      2306        6             679         2    2985     4
   Non-Hodgkin\'s lymphoma                              1846        5             1413        4    3259     4
                                                                                                             
  *Age*                                                                                                     
   \<45                                                 1156        3             3884        11   5040     7
   45--59                                               6624        18            10 578      29   17 202   24
   60--74                                               18 984      52            13 142      37   32 126   44
   \>75                                                 9859        27            8329        23   18 188   25
                                                                                                             
  *SES*                                                                                                     
   Low                                                  9518        26            9953        28   19 471   27
   Intermediate                                         14 309      39            13 824      38   28 133   39
   High                                                 10 812      30            9741        27   20 553   28
   Institution                                          1569        4             2032        6    3601     5
   Unknown                                              415         1             383         1    798      1
                                                                                                             
  *Comorbidity*                                                                                             
   *Number of concomitant diseases*                                                                         
    0                                                   10 688      29            14 826      41   25 514   35
    1                                                   10 775      29            9353        26   20 128   28
    \>2                                                 10 992      30            7050        20   18 042   25
    Unknown                                             4168        11            4704        13   8872     12
                                                                                                             
   *Concomitant disease*[a](#t1-fn2){ref-type="fn"}                                                         
    Previous cancer                                     4460        12            3565        10   7977     11
    Cardiovascular disease                              8353        23            3854        11   12127    17
    Peripheral arterial disease                         3445        9             1358        4    4767     7
    COPD                                                5347        15            2674        7    7994     11
    Hypertension                                        6367        17            7184        20   13 462   19
    Diabetes mellitus                                   3586        10            3482        10   7026     10
    Cerebrovascular disease                             1754        5             1044        3    2779     4
    Tuberculosis                                        553         2             409         1    947      1
    Central nervous system[b](#t1-fn3){ref-type="fn"}   221         1             354         1    568      1
    Gastrointestinal disease                            2629        7             1294        4    3900     5
    Other diseases                                      925         3             1078        3    1987     3
  Total                                                 36 623      50            35 933      50   72 556   100

Abbreviations: COPD=chronic obstructive pulmonary diseases; SES=socioeconomic status.

Patients may suffer from more than one condition.

Dementia in 96% of these patients.

###### Distribution of cancer patients newly diagnosed in 1997--2006 according to gender, age and socioeconomic status (SES)

                            **Males**   **Females**                                          
  ------------------------- ----------- ------------- -------- ----- -------- ----- -------- -----
  Oesophagus                589         23            342      37    170      30    161      43
  Stomach                   767         26            719      37    386      31    465      44
  Colorectal                3176        21            2662     32    2266     24    2630     40
  Pancreas                  433         24            339      36    325      28    374      44
  Lung                      4498        29            3827     38    2226     35    923      50
  Melanoma                  563         15            169      33    729      16    194      43
  Breast                    ---         ---           ---      ---   9070     21    3094     42
  Cervix uteri              ---         ---           ---      ---   476      37    120      43
  Corpus uteri              ---         ---           ---      ---   1189     25    576      42
  Ovary                     ---         ---           ---      ---   875      23    438      42
  Prostate                  3930        20            4149     30    ---      ---   ---      ---
  Kidney                    639         22            392      32    372      31    300      41
  Urinary bladder           855         25            1027     33    216      32    308      40
  Non-Hodgkin\'s lymphoma   1060        21            575      31    703      25    514      42
  Total of these sites      16 510      23            14 201   34    19 003   24    10 097   42

###### Risk of specific concomitant diseases according to SES adjusted for age and gender among cancer patients diagnosed in 1997--2006

                                   **SES**                                                                    
  -------------------------------- --------------------------------- --------------------------------- ------ --------
  Previous cancer                  1.01                              0.99                              1.00   0.7
  Cardiovascular disease           1.42[b](#t3-fn3){ref-type="fn"}   1.23[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  COPD                             1.81[b](#t3-fn3){ref-type="fn"}   1.37[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  Hypertension                     0.98                              1.03                              1.00   0.2
  Diabetes mellitus                1.52[b](#t3-fn3){ref-type="fn"}   1.32[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  Cerebrovascular disease          1.53[b](#t3-fn3){ref-type="fn"}   1.27[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  Tuberculosis                     1.34[b](#t3-fn3){ref-type="fn"}   1.17                              1.00   0.01
  Central nervous system           1.34[b](#t3-fn3){ref-type="fn"}   1.05                              1.00   0.05
  Gastrointestinal                 1.48[b](#t3-fn3){ref-type="fn"}   1.27[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  Other                            1.22[b](#t3-fn3){ref-type="fn"}   1.10                              1.00   0.01
  1 or more concomitant disease    1.50[b](#t3-fn3){ref-type="fn"}   1.24[b](#t3-fn3){ref-type="fn"}   1.00   0.0001
  2 or more concomitant diseases   1.80[b](#t3-fn3){ref-type="fn"}   1.36[b](#t3-fn3){ref-type="fn"}   1.00   0.0001

Abbreviations: COPD=chronic obstructive pulmonary diseases; SES=socioeconomic status.

*P* for overall effect of SES (χ^2^-likelihood ratio).

Confidence interval does not include 1.00.

###### Crude survival, risk of death, and contribution of comorbidity to risk of death according to tumour site and SES among cancer patients diagnosed in 1997--2006

                                      **1-year survival rate (%)**   **Model A[a](#t4-fn1){ref-type="fn"}**   **Model B[a](#t4-fn1){ref-type="fn"}**   **Relative contribution**                     
  ----------------------------------- ------------------------------ ---------------------------------------- ---------------------------------------- --------------------------- ----------------- -----
  *Males*                                                                                                                                                                                            
   Colorectum                         72                             78                                       78                                       1.13 (1.0--1.3)             1.10 (1.0--1.3)   23%
   Lung                               36                             39                                       41                                       1.11 (1.0--1.2)             1.11 (1.0--1.2)   0%
   Prostate                           90                             94                                       95                                       1.47 (1.2--1.8)             1.36 (1.1--1.7)   22%
   Total[d](#t4-fn4){ref-type="fn"}   59                             66                                       70                                       1.40 (1.3--1.5)             1.35 (1.3--1.4)   12%
                                                                                                                                                                                                      
  *Females*                                                                                                                                                                                          
   Colorectum                         74                             78                                       79                                       1.09 (0.9--1.3)             1.06 (0.9--1.2)   33%
   Lung                               41                             42                                       46                                       1.09 (1.0--1.2)             1.09 (1.0--1.2)   0%
   Breast                             94                             97                                       98                                       1.68 (1.3--2.2)             1.56 (1.2--2.0)   18%
   Total[d](#t4-fn4){ref-type="fn"}   74                             81                                       84                                       1.40 (1.3--1.5)             1.34 (1.3--1.4)   15%

Model A: adjusted for age, Model B: adjusted for age and the presence of concomitant diseases (yes *vs* no).

((HR model A−(HR model A+comorbidity))/(1−HR model A)) × 100.

Hazard Ratio (HR) of lowest socioeconomic status (SES) group compared with highest (=reference).

All studied sites combined (oesophagus, stomach, colorectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, kidney, urinary bladder, non-Hodgkin\'s lymphoma).
